Conivaptan

Vasopressin Receptor Antagonist — CARDIOVASCULAR SYSTEM

Key facts

Conivaptan is an ofp drug in the Vasopressin Receptor Antagonist class catalogued in DrugCentral. It was first approved by the FDA in 2005. Its mechanism of action is classified as Cytochrome P450 3A Inhibitors and Vasopressin Receptor Antagonists. DrugCentral lists 5 molecular targets, including AVPR2, AVPR1A and Avpr1a. Recorded indications include Hyponatremia.

• Approval status: ofp (first approved 2005 by the FDA).
• Drug class: Vasopressin Receptor Antagonist.
• Mechanism of action: Cytochrome P450 3A Inhibitors; Vasopressin Receptor Antagonists.
• Molecular targets: AVPR2, AVPR1A, Avpr1a and Avpr2 (5 listed in DrugCentral).
• Indications: Hyponatremia.
• ATC code: C03XA02 (Vasopressin antagonists).
• Molecular formula: C32H26N4O2; molecular weight 498.59 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Hyponatremia

Contraindications (9)

• Acute nephropathy
• Anuria
• Chronic heart failure
• Demyelination
• Disease of liver
• Hypernatremia
• Hypovolemia
• Kidney disease
• Osmotic Central Pontine Myelinolysis

Mechanism & targets

• Mechanism of action (MoA): Cytochrome P450 3A Inhibitors; Vasopressin Receptor Antagonists
• Established pharmacologic class: Vasopressin Receptor Antagonist

Molecular targets (5)

Target	Gene	Action	Activity
Vasopressin V2 receptor	AVPR2	antagonist	Ki 9.44
Vasopressin V1a receptor	AVPR1A	antagonist	Ki 9.37
Vasopressin V1a receptor	Avpr1a	unknown	Ki 9.32
Vasopressin V2 receptor	Avpr2	unknown	Ki 8.52
Oxytocin receptor	Oxtr	unknown	Ki 7.35

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2005-12-29	FDA	—	CUMBERLAND PHARMS

ATC classification

ATC code	Therapeutic hierarchy
C03XA02	CARDIOVASCULAR SYSTEM › DIURETICS › OTHER DIURETICS › Vasopressin antagonists

Chemical structure

• Molecular formula: C₃₂H₂₆N₄O₂
• Molecular weight: 498.59 g/mol
• CAS number: 168626-94-6
• InChIKey: IKENVDNFQMCRTR-UHFFFAOYSA-N
• PubChem CID: 151171

CC1=NC2=C(N1)C1=C(C=CC=C1)N(CC2)C(=O)C1=CC=C(NC(=O)C2=C(C=CC=C2)C2=CC=CC=C2)C=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Conivaptan used for?

DrugCentral lists the following indications for Conivaptan: Hyponatremia.

How does Conivaptan work?

Conivaptan is classified as Cytochrome P450 3A Inhibitors and Vasopressin Receptor Antagonists; its molecular targets in DrugCentral include AVPR2 (antagonist), AVPR1A (antagonist), Avpr1a and Avpr2.

When was Conivaptan first approved?

Conivaptan was first approved by the FDA in 2005.

What drug class does Conivaptan belong to?

Conivaptan is in the Vasopressin Receptor Antagonist class.

What is the chemical formula of Conivaptan?

Conivaptan has the molecular formula C32H26N4O2 and a molecular weight of 498.59 g/mol.

Sources

• DrugCentral drug card 732 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201108 — compound record and bioactivity
• PubChem CID 151171 — chemical identifiers
• DrugBank DB00872 — drug record
• FDA UNII 0NJ98Y462X — substance identity
• DailyMed: FDA labels for Conivaptan — current prescribing information (label search)
• UniProt P30518 (AVPR2) — target protein
• UniProt P37288 (AVPR1A) — target protein

How this page is built: methodology · editorial policy & corrections.